Dr. Mahran Shoukier, MD
Hematology & Oncology (Hematology & Oncology Physician)
1005 Harborside Dr Ste 1.230
Galveston, TX 77555
Who else practices at this address →
Galveston County includes primary care (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 22
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 106
Licensed in Texas since 2016, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license Q7964 (first issued 2016; active) -
Internal Medicine Physician
TX license Q7964 (first issued 2016; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Bon Secours St Marys Hospital Richmond, VA
- University of Texas Medical Branch Galveston Galveston, TX
- Houston Methodist Baytown Hospital Baytown, TX
- Bon Secours Richmond Community Hospital Richmond, VA
Medical groups
- Utmb Faculty Group Practice (1,101 clinicians)
- Bon Secours-Richmond Community Hospital LLC (43 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 106
- Services billed
- 9,383
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 67 | 28 |
| Established patient office or other outpatient visit, 30-39 minutes | 54 | 27 |
| New patient office or other outpatient visit, 45-59 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Galveston, TX | 33 |
| Eliquis (apixaban) Other prescribers in Galveston, TX | 31 |
| Dexamethasone Other prescribers in Galveston, TX | 18 |
| Xarelto (rivaroxaban) Other prescribers in Galveston, TX | 17 |
| Ondansetron Odt (ondansetron) Other prescribers in Galveston, TX | 16 |
| Olanzapine Other prescribers in Galveston, TX | 16 |
| Tramadol Hcl Other prescribers in Galveston, TX | 15 |
| Gabapentin Other prescribers in Galveston, TX | 15 |
| Prednisone Other prescribers in Galveston, TX | 14 |
| Famciclovir | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 16 companies reported 29 payments worth $781 in total to this clinician.
| Tempus Ai, Inc | $93.75 |
|---|---|
| Novartis Pharmaceuticals Corporation | $92.34 |
| AstraZeneca Pharmaceuticals LP | $86.11 |
| E.r. Squibb & Sons, L.l.c. | $77.68 |
| Merck Sharp & Dohme LLC | $60.56 |
| Tersera Therapeutics LLC | $54.14 |
| Daiichi Sankyo Inc. | $47.62 |
| Janssen Pharmaceuticals, Inc | $46.28 |
| Food and Beverage | $781 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $309,465 in research payments for these studies, mostly to the institutions running them.
- A phase 1 study of SGNB6A in advanced solid tumors
Pfizer Inc. - A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.…
Amgen Inc. - Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
AbbVie Inc. · Active, not recruiting · NCT05029882 - A phase 1B evaluating safety, efficacy, pk and pd of glofitamab plus gem-ox in rem ptswith r/r dlbcl
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.